Vertex and crispr therapeutics present new data in 22 patients with greater than 3 months follow-up post-treatment with investigational crispr/cas9 gene-editing therapy, ctx001™ at european hematology association annual meeting

Boston & zug, switzerland & cambridge, mass.--(business wire)--vertex pharmaceuticals incorporated (nasdaq:vrtx) and crispr therapeutics (nasdaq:crsp) today announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational crispr/cas9-based gene-editing therapy, ctx001, that show a consistent and sustained response to treatment. ctx001 is being investigated in two ongoing phase 1/2 clinical trials as a potential one-
VRTX Ratings Summary
VRTX Quant Ranking